Press release
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 – CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 –\n\n\n CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Washington, DC from February 23-26.\n\n\nThe following presentations will take place on Saturday, February 24, 2024 from 9:45 - 10:45 am ET in the Convention Center, Level 2, Hall D.\n\n\n\nCharacteristics of Hereditary Angioedema Attacks Among Long-Term Prophylaxis Users (#215): Bob Geng, Vibha Desai, Julie Ulloa, Sherry Danese, Shawn Czado, Paul K. Audhya, Timothy Craig. Results shared as an oral poster presentation and Q&A\n\n\n\nDelayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers (#216): Sandra Christiansen, Maeve O’Connor, Julie Ulloa, Sherry Danese, Vibha Desai, Shawn Czado, Paul Audhya, Paula Busse. Results shared as an oral poster presentation and Q&A\n\n\n\nAnxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks (#257): James Wedner, Cristine Radojicic, Julie Ulloa, Sherry Danese, Vibha Desai, Shawn Czado, Paul Audhya, Sandra Christiansen. Results shared as an oral poster presentation and Q&A\n\n\n\nAnxiety Associated with Refilling On-demand Therapy for HAE Attacks Contributes to Treatment Delay and Non-Treatment (#258): Daniel F. Soteres, Anete S. Grumach, Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, Autumn Burnette. Results shared as an oral poster presentation and Q&A\n\n\n\nCharacterizing the Negative Impact of Delayed On-Demand Treatment of HAE Attacks (#260): Princess Ogbogu, Hilary Longhurst, Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, Ricardo Zwiener. Results shared as an oral poster presentation and Q&A\n\n\n\nThe Impact of On-demand Treatment on Quality of Life of People with HAE (#265): Paula Busse, Bob Geng, Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, Douglas H. Jones. Results shared as an oral poster presentation and Q&A\n\n\n\nCharacterizing the Perspective of Patients with HAE on Prophylactic...